Jupiter Neurosciences Inc's Business Segments

The company is a pharmaceutical firm focused on developing and commercializing drug products, primarily its proprietary drug delivery platform, JOTROL™. It has not generated significant revenue from product sales and has incurred substantial net losses since inception, with expectations of continued losses in the foreseeable future. Its operations and future prospects depend on an exclusive worldwide license agreement with Aquanova for the Nugevia brand and pharmaceutical products. The company is currently focused on developing JOTROL™ for specific indications but acknowledges the risk of not pursuing other potentially profitable indications or product candidates. Clinical drug development involves lengthy, costly, and uncertain processes, including potential regulatory challenges from the FDA, EMA, and other authorities. The company faces risks related to indebtedness from convertible promissory notes, the need for additional capital which may dilute stockholders or limit operations, competition from other technologies or products, and regulatory and market uncertainties. Additional risks include stock price volatility, low trading volume, and the potential for delisting from The Nasdaq Capital Market. The company remains in a developmental stage with significant financial and operational risks affecting its ability to continue as a going concern.

Effective October 1, 2025, the Company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for the central nervous system (CNS). The Chief Executive Officer, who serves as the Chief Operating Decision Maker (CODM), evaluates financial performance and allocates resources based on the operating results of these segments. Segment performance is primarily assessed using segment net loss or income. Selling, general, and administrative expenses are either directly attributable to the segments or allocated using reasonable and consistently applied methodologies. Corporate and other expenses not allocated to the reportable segments include public company costs, certain executive compensation, certain stock-based compensation, interest income and expense, other income and expense, and income taxes. Prior-period information has been recast to conform to the current presentation reflecting these two reportable segments.